HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PAN2
poly(A) specific ribonuclease subunit PAN2
Chromosome 12 Β· 12q13.3
NCBI Gene: 9924Ensembl: ENSG00000135473.17HGNC: HGNC:20074UniProt: Q504Q3
51PubMed Papers
20Diseases
0Drugs
6Pathogenic Variants
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
3'-5'-RNA exonuclease activitypoly(A)-specific ribonuclease activityprotein bindingnuclear-transcribed mRNA poly(A) tail shorteningneurodegenerative diseaseGlobal developmental delayAnorectal anomalyEEG abnormality
✦AI Summary

PAN2 is the catalytic subunit of the PAN2-PAN3 deadenylation complex, one of two major cytoplasmic mRNA deadenylases responsible for poly(A) tail shortening 1. PAN2 catalyzes 3'-5' exonucleolytic degradation of mRNA poly(A) tails in a manner stimulated by poly(A)-binding protein (PABPC1) 2, with activity on long poly(A) tails characteristic of mammalian mRNAs 2. This deadenylation represents the rate-limiting and often initial step in mRNA degradation across multiple decay pathways 3. Following PAN2-mediated shortening, the CCR4-NOT complex continues degradation, with deadenylated mRNAs subsequently degraded via exosome-mediated or decapping-dependent pathways 1. PAN2 also facilitates mRNA processing body (P-body) formation and function, playing structural and functional roles beyond substrate preparation 4. Beyond canonical deadenylation, PAN2 possesses deubiquitinase activity and regulates HIF1A mRNA stability during hypoxic response independent of poly(A) tail modulation. Disease associations include skeletal dysplasia, where PAN2 variants are proposed as candidate disease genes 5, and bladder cancer, where PAN2 (also designated USP52) modulates ferroptosis susceptibility through xCT protein stability regulation 6.

Sources cited
1
PAN2-PAN3 are cytoplasmic deadenylases that shorten poly(A) tails, with activity stimulated by PABPC; followed by CCR4-NOT complex degradation
PMID: 34594027
2
PAN2-PAN3 complex shows greater activity on long poly(A)-PABPC1 substrates characteristic of mammals; structural adaptation to recognize longer poly(A) tails
PMID: 41275497
3
PAN2-PAN3 mediates initial deadenylation as rate-limiting step in mRNA degradation across multiple decay pathways
PMID: 21957004
4
Deadenylation by deadenylases plays indispensable role in P-body formation and regulation structurally and functionally
PMID: 23224971
5
PAN2 proposed as candidate disease gene with suggestive biological links to skeletal dysplasia
PMID: 29620724
6
USP52/PAN2 has deubiquitinase activity; stabilizes xCT protein and regulates ferroptosis in bladder cancer; high USP52 associated with aggressive disease and poor prognosis
PMID: 39392373
Disease Associationsβ“˜20
neurodegenerative diseaseOpen Targets
0.50Moderate
Global developmental delayOpen Targets
0.37Weak
Abnormality of blood and blood-forming tissuesOpen Targets
0.37Weak
Abnormality of head or neckOpen Targets
0.37Weak
Abnormality of the cardiovascular systemOpen Targets
0.37Weak
Abnormality of the eyeOpen Targets
0.37Weak
Abnormality of the skeletal systemOpen Targets
0.37Weak
Anorectal anomalyOpen Targets
0.37Weak
disease of genitourinary systemOpen Targets
0.37Weak
EEG abnormalityOpen Targets
0.37Weak
Intellectual disabilityOpen Targets
0.37Weak
SeizureOpen Targets
0.37Weak
Sensorineural hearing impairmentOpen Targets
0.37Weak
psoriasisOpen Targets
0.18Weak
psoriasis vulgarisOpen Targets
0.09Suggestive
colorectal carcinomaOpen Targets
0.08Suggestive
coronary artery diseaseOpen Targets
0.08Suggestive
type 2 diabetes mellitusOpen Targets
0.07Suggestive
bladder transitional cell carcinomaOpen Targets
0.07Suggestive
non-small cell lung carcinomaOpen Targets
0.07Suggestive
Pathogenic Variants6
NM_014871.6(PAN2):c.3354G>A (p.Trp1118Ter)Pathogenic
Developmental delay with variable cardiac and renal congenital anomalies and dysmorphic facies
β˜…β˜†β˜†β˜†2025β†’ Residue 1118
NM_014871.6(PAN2):c.2326G>T (p.Glu776Ter)Pathogenic
PAN2-related multiple congenital anomalies syndrome|Developmental delay with variable cardiac and renal congenital anomalies and dysmorphic facies
β˜†β˜†β˜†β˜†2025β†’ Residue 776
NM_014871.6(PAN2):c.3399dup (p.Glu1134Ter)Pathogenic
PAN2-related multiple congenital anomalies syndrome|Developmental delay with variable cardiac and renal congenital anomalies and dysmorphic facies
β˜†β˜†β˜†β˜†2025β†’ Residue 1134
NM_014871.6(PAN2):c.3153del (p.Ser1052fs)Pathogenic
Developmental delay with variable cardiac and renal congenital anomalies and dysmorphic facies
β˜†β˜†β˜†β˜†2025β†’ Residue 1052
NM_014871.6(PAN2):c.3026T>A (p.Val1009Asp)Pathogenic
Developmental delay with variable cardiac and renal congenital anomalies and dysmorphic facies
β˜†β˜†β˜†β˜†2025β†’ Residue 1009
NM_014871.6(PAN2):c.574-2A>GLikely pathogenic
PAN2-related multiple congenital anomalies syndrome
β˜†β˜†β˜†β˜†2022
View on ClinVar β†—
Related Genes
TNRC6CProtein interaction100%PABPC4Protein interaction96%PABPC1Protein interaction96%PAN3Protein interaction88%PABPC1LProtein interaction74%USP50Protein interaction73%
Tissue Expression6 tissues
Liver
100%
Ovary
82%
Bone Marrow
55%
Lung
36%
Heart
33%
Brain
16%
Gene Interaction Network
Click a node to explore
PAN2TNRC6CPABPC4PABPC1PAN3PABPC1LUSP50
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q504Q3
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.59Moderately Constrained
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.48 [0.40–0.59]
RankingsWhere PAN2 stands among ~20K protein-coding genes
  • #8,707of 20,598
    Most Researched51
  • #3,396of 5,498
    Most Pathogenic Variants6
  • #4,043of 17,882
    Most Constrained (LOEUF)0.59 Β· top quartile
Genes detectedPAN2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression.
PMID: 34594027
Nat Rev Mol Cell Biol Β· 2022
1.00
2
Expanding the phenome and variome of skeletal dysplasia.
PMID: 29620724
Genet Med Β· 2018
0.90
3
Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT.
PMID: 39392373
Adv Sci (Weinh) Β· 2024
0.80
4
mRNA deadenylation by Pan2-Pan3.
PMID: 24450649
Biochem Soc Trans Β· 2014
0.70
5
Deadenylation and P-bodies.
PMID: 23224971
Adv Exp Med Biol Β· 2013
0.60